Gilead Sciences has reported net income for the fourth quarter 2016 of $3.1 billion, which is $1.6 billion less compared to same period last year.
Full year 2016 net income was $13.5 billion, down $4,6 billion compared to last year.
The company said that lower net income is due decline in sales of its HCV products, Harvoni, Sovaldi and partially offset by sales of Epclusa, which was launched in 2016 across various locations.
Sales of these products for 2016 is $14,8 billion, which is $4,3 billion less compared to last year.